The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Large Is The Oral Solid Dosage Pharmaceutical Formulation Market Projected To Become By 2030 Based On Its 2026 Valuation?
The oral solid dosage pharmaceutical formulation market has experienced significant growth in recent years. This market is projected to expand from $653.26 billion in 2025 to reach $692.14 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 6.0%. Historically, this expansion has been driven by several factors, including the broad acceptance of oral drug delivery, a well-developed manufacturing infrastructure for tablets and capsules, the increasing incidence of chronic diseases, the cost-effectiveness of oral solid dosage forms, and a strong regulatory understanding of oral formulations.
The oral solid dosage pharmaceutical formulation market is projected to experience robust expansion over the coming years. This market is anticipated to reach $846.38 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.2%. Factors contributing to this growth during the forecast period include the increasing demand for long-acting oral medications, a heightened emphasis on patient adherence and convenience, the expansion of pharmaceutical outsourcing and CDMO services, an increase in global generic drug production, and advancements in excipients and formulation technologies. Key trends characterizing this period encompass the increasing embrace of controlled and modified-release dosage forms, a rising demand for patient-friendly oral solid formats, the broadening of generic and branded solid dosage manufacturing, a greater focus on high-bioavailability formulations, and a move towards cost-optimized and scalable oral dosage production.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15626&type=smp
What Primary Drivers Are Shaping The Development Of The Oral Solid Dosage Pharmaceutical Formulation Market?
The escalating occurrence of chronic illnesses is anticipated to boost the expansion of the oral solid dosage pharmaceutical formulation market in the future. These are defined as enduring health conditions that persist for prolonged durations, generally exceeding three months. The increasing incidence of chronic diseases can be attributed to factors such as an aging demographic, inactive lifestyles, inadequate dietary choices, environmental influences, and enhanced diagnostic capabilities. Oral solid dosage pharmaceutical formulations are crucial for managing chronic diseases and fostering patient adherence to long-term treatments, given their convenience, stability, and accurate dosing. A notable example is the World Health Organization’s projection, released in February 2024 by the Switzerland-based intergovernmental organization, indicating more than 35 million new cancer cases by 2050, which signifies a 77% surge from the approximately 20 million cases estimated in 2022. Consequently, the growing prevalence of chronic diseases significantly contributes to the growth of the oral solid dosage pharmaceutical formulation market.
What Segment Groups Are Identified Within The Oral Solid Dosage Pharmaceutical Formulation Market?
The oral solid dosage pharmaceutical formulation market covered in this report is segmented –
1) By Dosage Form: Tablets, Capsules, Powders And Granules, Lozenges And Pastilles, Gummies
2) By Mechanism: Controlled-Release, Immediate-Release, Delayed-Release
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies, Hypermarkets Or Supermarkets
4) By End-User: Large-Size Companies, Medium And Small-Size Companies, Other End-Users
Subsegments:
1) By Tablets: Immediate-Release Tablets, Extended-Release Tablets, Controlled-Release Tablets, Effervescent Tablets, Chewable Tablets, Sublingual Tablets
2) By Capsules: Hard Gelatin Capsules, Soft Gel Capsules, Liquid-Filled Capsules, Delayed-Release Capsules
3) By Powders And Granules: Oral Powders (Reconstitution), Granules (Oral Suspension Or Dispersible Granules)
4) By Lozenges And Pastilles: Medicinal Lozenges, Herbal Lozenges, Sugar-Free Lozenges, Pastilles ( Throat Or Cough Relief)
5) By Gummies: Vitamin Gummies, Herbal And Nutritional Supplement Gummies, Pharmaceutical Gummies ( Pain Relief Or Sleep Aids)
What Trends Are Advancing Progress In The Oral Solid Dosage Pharmaceutical Formulation Market?
Major companies in the Oral Solid Dosage (OSD) pharmaceutical market are concentrating on developing innovative solutions, such as fixed dose combinations, to improve efficacy, patient compliance, and safety. A fixed dose combination (FDC) is a medicine comprising two or more active drugs combined in a single dosage form, aiming to simplify treatment and enhance patient adherence. For example, in February 2025, Ono Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, gained approval from the U.S. Food and Drug Administration (FDA) for Journavex (suzetrigine) 50 mg oral tablets, indicated for treating moderate to severe acute pain in adults. Its mechanism involves selectively inhibiting NaV1.8 sodium channels in the peripheral nervous system, which blocks pain signals before they reach the brain, providing effective pain relief without risks of addiction. Clinical trials showed significant pain reduction compared to a placebo, alongside a well-tolerated safety profile including mild side effects like itching and muscle spasms.
Which Companies Hold Significant Positions In The Oral Solid Dosage Pharmaceutical Formulation Market?
Major companies operating in the oral solid dosage pharmaceutical formulation market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc., Novartis AG, Hoffman-La-Roche Ltd., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim GmbH, Gilead Sciences, Amgen Inc., Teva Pharmaceuticals, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Biogen Inc., Lonza Group, Catalent Inc., Ashland Inc., Piramal Pharma Solutions, Jubilant Pharmova, CordenPharma International
Read the full oral solid dosage pharmaceutical formulation market report here:
How Does The Oral Solid Dosage Pharmaceutical Formulation Market Perform Across Major Global Regions?
North America was the largest region in the oral solid dosage pharmaceutical formulation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral solid dosage pharmaceutical formulation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Oral Solid Dosage Pharmaceutical Formulation Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=15626&type=smp
Browse Through More Reports Similar to the Global Oral Solid Dosage Pharmaceutical Formulation Market 2026, By The Business Research Company
Oral Solid Dosage Pharmaceutical Formulation Market Report 2026
Oral Solid Dosage Contract Manufacturing Market Report 2026
Drug Formulation Market Report 2026
https://www.thebusinessresearchcompany.com/report/drug-formulation-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model